Information Provided By: 
Fly News Breaks for September 16, 2019
BIIB
Sep 16, 2019 | 14:40 EDT
RBC Capital analyst Brian Abrahams noted that Biogen's Phase II study of BG00011, formerly STX-100, has been discontinued due to toxicity, and he confirmed this with the company. However, the analyst does not believe the discontinuation will impact shares or valuation, but added that "it does underscore some of the relatively high-risk nature of BIIB's pipeline and removes one of their potential internal diversification opportunities."
News For BIIB From the Last 2 Days
